5Stevens DA. Therapy for opportunistic fungal infectious: past,present and future[ J ]. Indian J Cancer, 1995,32 (1) : 1.
6Powderly WG,Keath M, Anderson S, et al. Amphotericin B-resistant Cyptococcus neoformans in a patient with AIDS[J]. Infect Dis Clin Pract , 1990,1 : 314.
7Louie A,Kaw P,Banerjee P, et al. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endoearditis and pyelonephritis [ J ]. Anti Agents Chem ,2001,45(2) :485.
8Yamaguchi H. Molecular and biochemical mechanisms of drug resistance in fungi [ J ]. Nippon Ishinkin Gakkai Zasshi, 1999,40(4) : 199.
9Kohli A,Smriti,Mukhopadhyay K, et al. In vitro low-level resistance to azoles in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry[J]. Anti Agents Chem,2002,46(4): 1046.
10Loftier J, Einsele H, Hebart H, et al. Phospholipid and sterol analysis of plasma membranes of azole-resistant Candida albicans strains[J]. FEMS Microbiol Lett ,2000,185(1) :59.
4Pereira GH, Muller PR, Szeszs MW,et al. Five-year evaluation of bloodstream yeast infections in a tertiary hospital: the predominance of non-C.albicans Candida species. Med Mycol. 2010 Sep;48(6):839-42.
5Bremenkamp RM, Caris AR, Jorge AO, et al.Prevalence and antifungal resistance profile of Candida spp. oral isolates from patients with type 1 and 2 diabetes mellitus.Arch Oral Biol. 2011;56(6):549-55.
9Park S,Kelly R,Kahn J N,et al.Specific substitutions in the echinocandin target fksl P account for reduced susceptibility of rare laboratory and clinical Candida sp.Isolates Amimiemb[J].Agents Chemother,2005,49:3264 - 3273.
10Rodriquez-Tudela J L,DonneHy J P,Pfaller M A.Statistical analyses of correlation between fluconazoleMICs for Candida spp.Assessed by standardmethods set foah by the European Committee Oil Antimicmbial Susceptibility Testing (E.Dis.7.1) and CLS - (M27-A2)[J].J Clin Microbiol,2007,45:109.
